Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Regulus Therapeutics licenses microRNA technology from Caltech
February 2010
SHARING OPTIONS:

CARLSBAD, Calif.Regulus Therapeutics Inc., a biopharmaceutical company founded by Alnylam Pharmaceuticals Inc. and Isis Pharmaceuticals Inc., announced in December that it has licensed inventions made in the laboratory of Dr. David Baltimore at the California Institute of Technology covering methods and compositions for modulating microRNA-146 and microRNA-155. Baltimore and his colleagues have shown that microRNAs miR-146 and miR-155 are key mediators of the inflammatory response. According to Regulus, modulation of these microRNAs could lead to a new method of treating immune-inflammatory disease. Financial details were not released.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.